



THE UNIVERSITY *of* EDINBURGH

## Edinburgh Research Explorer

### Early PREdiction of Sepsis using leukocyte surface biomarkers:

**Citation for published version:**

Shankar-Hari, M, Datta, D, Wilson, J, Assi, V, Stephen, J, Weir, CJ, Rennie, J, Antonelli, J, Bateman, A, Felton, JM, Warner, N, Judge, K, Keenan, J, Wang, A, Burpee, T, Brown, KA, Lewis, SM, Mare, T, Roy, AI, Wright, J, Hulme, G, Dimmick, I, Gray, A, Rossi, AG, Simpson, AJ, Conway-Morris, A & Walsh, T 2018, 'Early PREdiction of Sepsis using leukocyte surface biomarkers: The ExPRES-Sepsis cohort study', *Intensive Care Medicine*, vol. 44, pp. 1836-1848. <https://doi.org/10.1007/s00134-018-5389-0>

**Digital Object Identifier (DOI):**

[10.1007/s00134-018-5389-0](https://doi.org/10.1007/s00134-018-5389-0)

**Link:**

[Link to publication record in Edinburgh Research Explorer](#)

**Document Version:**

Peer reviewed version

**Published In:**

Intensive Care Medicine

**Publisher Rights Statement:**

This is the author's peer-reviewed manuscript as accepted for publication.

**General rights**

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [openaccess@ed.ac.uk](mailto:openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.



# Early PREdiction of Sepsis using leukocyte surface

## biomarkers: The ExPRES-Sepsis cohort study

**Running title:** Risk of sepsis using leukocyte cell surface makers

Manu Shankar-Hari PhD<sup>1,2C</sup>, Deepankar Datta MRCEM<sup>3</sup>, Julie Wilson FRCA<sup>1,2</sup>,  
Valentina Assi PhD<sup>4,5</sup>, Jacqueline Stephen PhD<sup>5</sup>, Christopher J Weir PhD<sup>4,5</sup>, Jillian  
Rennie BSc<sup>3</sup>, Jean Antonelli BSc(Hons)<sup>4</sup>, Anthony Bateman MD<sup>6</sup>, Jennifer Felton  
PhD<sup>3</sup>, Noel Warner PhD<sup>7</sup>, Kevin Judge MD<sup>7</sup>, Jim Keenan BSc<sup>7</sup>, Alice Wang PhD<sup>7</sup>,  
Tony Burpee BSc(Hon)<sup>7</sup>, Alun K Brown MB ChB, PhD<sup>2</sup>, Sion M Lewis PhD<sup>2</sup>, Tracey  
Mare MSc<sup>2</sup>, Alistair I Roy FRCA<sup>7</sup>, John Wright FRCS MRCP<sup>8</sup>, Gillian Hulme PhD<sup>9</sup>,  
Ian Dimmick MSc<sup>9</sup>, Alasdair Gray MD<sup>4 10</sup>, Adriano G Rossi PhD DSc<sup>3</sup>, A John  
Simpson PhD<sup>11</sup>, Andrew Conway Morris PhD<sup>12</sup>, Timothy S Walsh MD<sup>3,4,5</sup>

<sup>1</sup>School of Immunology & Microbial Sciences, Kings College London, UK

<sup>2</sup>Guy's and St Thomas' NHS Foundation Trust, London, UK

<sup>3</sup>MRC Centre for Inflammation Research, University of Edinburgh, 47 Little France  
Crescent, Edinburgh, UK

<sup>4</sup>Centre for Population Health Sciences, Usher Institute, University of Edinburgh, UK

<sup>5</sup>Edinburgh Clinical Trials Unit, University of Edinburgh, UK

<sup>6</sup>Department of Anaesthesia, Critical Care & Pain Medicine, University of Edinburgh,  
UK

<sup>7</sup>Becton Dickinson Bioscience – Franklin Lakes, NJ, USA

<sup>7</sup>Integrated Critical Care Unit, Sunderland Royal Hospital, Sunderland, UK

<sup>8</sup>Emergency Department, Royal Victoria Infirmary, Newcastle Upon Tyne Hospitals  
NHS Foundation Trust, UK

<sup>9</sup>Flow Cytometry Core Facility Laboratory, Faculty of Medical Sciences, Centre for Life, Newcastle University, Newcastle upon Tyne, UK

<sup>10</sup>Department of Emergency Medicine, Royal Infirmary of Edinburgh, Edinburgh, UK

<sup>11</sup>Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK

<sup>12</sup>University Division of Anesthesia, Department of Medicine, Addenbrooke's Hospital, Hills Road, Cambridge, UK

**<sup>c</sup> Corresponding author:**

**Dr Manu Shankar-Hari MSc PhD FRCA FFICM**

NIHR Clinician Scientist & Consultant Physician in Critical Care Medicine

1<sup>st</sup> Floor, East Wing, St Thomas' Hospital, Guy's and St Thomas' NHS Foundation Trust London, UK, SE17EH; <sup>1</sup>School of Immunology & Microbial Sciences, Kings College London, UK

email: [manu.shankar-hari@kcl.ac.uk](mailto:manu.shankar-hari@kcl.ac.uk)

Tel: +44 20 7188 8769; Fax: +44 20 7188 2284

**Author contributions**

Drs Shankar-Hari, Weir and Walsh had full access to all the data in the study and take responsibility for integrity of data and the accuracy of the data analyses.

*Concept and design:* Walsh, Simpson, Conway Morris, Datta, Weir, Warner

*Statistical analysis:* Assi, Stephen, Weir, Datta, Wilson, Shankar-Hari

*Drafting of manuscript:* Shankar-Hari, Weir, Walsh

*Acquisition, analysis and interpretation of data:* All authors

*Critical revision of the manuscript for important intellectual content:* All authors

*Obtained funding:* Walsh, Conway Morris, Brown, Simpson, Warner, Keenan

*Administrative, technical, or material support:* Walsh, Weir, Warner, Judge. Keenan

*Supervision:* Walsh, Weir

All authors confirm to the accuracy or integrity of the work.

### **Sources of support:**

The study was funded by Innovate UK (Sepsis 2: 101193). Dr Shankar-Hari is supported by the National Institute for Health Research Clinician Scientist Award (CS-2016-16-011). Dr Conway Morris is supported by a Clinical Research Career Development Fellowship from the Wellcome Trust (WT 2055214/Z/16/Z).

### **Conflicts of interests:**

Noel Warner, Kevin Judge, Jim Keenen and Alice Wang were all employees of BD biosciences whilst this work was being undertaken, and all four authors hold stock in BD Biosciences. Prof Simpson collaborated with BDB on a Wellcome Trust/Department of Health-funded Healthcare Innovation Challenge Fund (HICF) grant in suspected ventilator-associated pneumonia. He is Director of the NIHR Newcastle In Vitro Diagnostic Evidence Co-operative (formerly the NIHR Newcastle Diagnostic Evidence Co-operative) – these entities exist to evaluate in vitro diagnostics and have worked with (and continue to work with) BDB and other companies in this capacity. All other authors declare that they do not have any personal conflict of interest directly related to this manuscript.

### **Figures and tables; References and Supplementary material**

Tables = 4; Figures = 1; References = 50; Supplementary material = 24 pages

### Take home message:

In this first study of standardised multi-site flow cytometry in acutely unwell patients with suspected infections attending emergency departments, we explored which of 47 leukocyte biomarkers reliably discriminates which patients develop sepsis over the next 3 days, defined according to the Sepsis-3 sepsis criteria.

After highlighting the importance of test reliability (14 biomarkers lacked measurement reliability) and comparator cohorts (a further 17 biomarkers did not discriminate acutely unwell patients with suspected infection from patients with established sepsis-related critical illness and/or non-infective acute illness), we found that none of the remaining 16 biomarkers had clinically relevant predictive ability for subsequent sepsis or other important clinical outcomes. However, markers of early immune suppression (neutrophil and monocyte CD274 and CD279; monocyte HLA-DR) had the strongest associations with clinical outcomes. The optimum biomarker combination associated with clinical deterioration to sepsis was increased neutrophil CD24 and CD279 and reduced monocyte HLA-DR expression.

## **Abstract**

### **Purpose:**

Reliable biomarkers for predicting subsequent sepsis among patients with suspected acute infection are lacking. In patients presenting to emergency departments (EDs) with suspected acute infection, we aimed to evaluate the reliability and discriminant ability of 47 leukocyte biomarkers as predictors of sepsis (Sequential Organ Failure Assessment score  $\geq 2$  at 24 hours and/or 72 hours following ED presentation).

### **Methods:**

In a multi-centre cohort study in four EDs and intensive care units (ICUs), we standardised flow-cytometric leukocyte biomarker measurement, and compared patients with suspected acute infection (cohort-1), with two comparator cohorts: ICU patients with established sepsis (cohort-2); and ED patients without infection or systemic inflammation but requiring hospitalization (cohort-3).

### **Results:**

Between January 2014 and February 2016, we recruited 272, 59 and 75 patients to cohorts 1, 2, and 3 respectively. Of 47 leukocyte biomarkers, 14 were non-reliable, and 17 did not discriminate between the three cohorts. Discriminant analyses for predicting sepsis within cohort-1 were undertaken for eight neutrophil (cluster of differentiation antigens (CD) CD15;CD24;CD35;CD64;CD312;CD11b;CD274;CD279), seven monocyte (CD35;CD64;CD312;CD11b;HLA-DR;CD274;CD279) and a CD8 T-lymphocyte biomarker (CD279). Individually, only higher neutrophil CD279 (OR 1.78 (95%CI:1.23-2.57);P=0.002), higher monocyte CD279 (1.32 (1.03-1.70);P=0.03), and lower monocyte HLA-DR (0.73 (0.55-0.97);P=0.03) expression were associated with subsequent sepsis. With logistic regression the optimum biomarker combination was increased neutrophil CD24 and neutrophil CD279, and

reduced monocyte HLA-DR expression, but no combination had clinically relevant predictive validity.

**Conclusions:**

From a large panel of leukocyte biomarkers, immunosuppression biomarkers were associated with subsequent sepsis in ED patients with suspected acute infection.

**Clinical trial registration: NCT02188992**

**Key words**

Sepsis; infection; mortality; cohort study; biomarker, risk prediction

## Introduction

Sepsis is life-threatening organ dysfunction caused by a dysregulated host response to infection[1]. Host immune responses result from leukocytes sensing pathogen- and tissue damage-associated danger signals[2, 3]. Sepsis-related immune responses involve both humoral and leukocyte components of the innate and adaptive immune systems, with excessive inflammation and immunosuppression occurring simultaneously in most patients[2, 3]. These are thought to influence the resulting clinical phenotypes and outcomes[3, 4].

Leukocyte responses in sepsis measured using flow cytometry detects leukocyte biomarkers, including surface markers and/or leukocyte subsets[5]. Previous flow cytometry-based leukocyte biomarker studies in sepsis were mostly small single centre studies in patients with sepsis, typically focusing on a limited panel of biomarkers. These studies rarely evaluated biomarker reliability and reproducibility, which is methodologically and clinically relevant as it influences diagnostic validity[6]. In addition, few studies used robust unbiased designs to assess predictive ability for clinically relevant outcomes in unselected populations with suspected infections *prior* to developing organ dysfunction and established sepsis.

We hypothesized that among patients with clinically suspected acute infection but without established sepsis, leukocyte biomarkers would identify patients who subsequently deteriorate clinically and develop sepsis, when measured within a few hours of presentation to the emergency department (ED). Our study objectives were: (1) to identify reliable leukocyte biomarkers; (2) to ascertain which of the reliable biomarkers could discriminate[6] acutely unwell patients with suspected infection from patients with community acquired sepsis-related critical illness in the intensive care unit (ICU) and/or ED patients with non-infective acute illness requiring



hospitalisation; and, (3) to ascertain whether any of the reliable biomarkers with cross-cohort discrimination could predict which patients with suspected infection in the ED subsequently develop sepsis. We also undertook a post hoc extreme phenotype analysis[7], to compare the biomarker profiles between acutely unwell patients with suspected infection who subsequently developed most severe illness with those who recovered rapidly.

## **Methods**

### **Study sites and ethics**

We performed a prospective, multi-centre, observational cohort study at four sites in the United Kingdom. Ethical approval was granted by the Scotland A/Oxford C Research Ethics Committees (13/SS/0023;13/SC/0266). Consent was provided by patients or surrogate decision-makers according to capacity. We registered the study (NCT02188992) and published the protocol including the analysis plan[8].

### **Cohort definitions and eligibility criteria**

We recruited three distinct patient cohorts using an a priori sampling method to achieve similar age and sex profiles across the ED cohorts. Detailed inclusion/exclusion criteria are listed in the electronic supplement and published protocol (emethods-1)[8]. Cohort-1 comprised acutely unwell patients with suspected infection and systemic inflammation presenting to ED and formed the “discovery cohort”. Patients considered by clinical teams to already have established severe sepsis and/or require ICU admission when screened were excluded. Cohort-2 comprised ICU patients with established community acquired sepsis-related critical illness and formed the “true positive” cohort. Cohort-3 comprised acutely ill patients presenting to ED without infection or systemic inflammation but requiring

hospitalization and formed the “true negative” cohort. Inclusion criteria used throughout the study were based on the sepsis definitions by Levy et al [9], as our study was designed prior to the Sepsis-3 definitions[1, 10]. All ED patients were enrolled within 12-hours of hospital presentation. For all cohorts, we excluded patients with acute pancreatitis, haematological malignancy, chemotherapy in the past 2-weeks, myelodysplastic syndromes, known neutropenia, HIV infection, viral hepatitis infection, pregnancy, blood transfusion >4units in past week, oral corticosteroids for >24hours prior to enrolment, or a decision not for active therapy/for palliative care[8].

### **Leukocyte surface biomarkers and cross-site standardization of flow cytometry**

We devised 5 separate flow cytometry panels to assess 47 leukocyte biomarkers with biological plausibility for having predictive validity for subsequent sepsis (eMethods-1; eTable-1; eFigure-1). We developed, standardized and harmonized flow cytometry procedures across all 4 study sites[8]. We performed flow cytometry within 4-hours of sample acquisition. All anti-human antibodies conjugated to fluorochromes for flow cytometry were from the same batch and clones (all Becton Dickinson Biosciences (BDB)), standardized on the same platform (FACSCanto II; BDB, San Jose, CA, USA), using a common batch of Cytometry Setup and Tracking beads with the same beads for daily internal quality controls, at all clinical sites. All flow cytometry standard (FCS) files were read by expert technicians using standardized gating procedures developed for each biomarker prior to analysis. The gating strategy for estimating median fluorescence intensity (MFI) or proportions is reported in eMethods-1. All FCS analysis technicians were blinded from clinical data.

## Sample size

We based sample size estimates on the confidence interval (CI) widths for positive and negative predictive values (PPV and NPV). The initial design had a primary outcome of septic shock, with an estimated event rate of 5–10% in cohort-1[11, 12]. For a range in test performance for PPV/NPV of 50%-90% we planned a sample size of: cohort-1, n=300; cohort-2, n=100; and cohort-3, n=100, to give a CI width between  $\pm 4.6\%$  to  $\pm 9.8\%$  for PPV, and  $\pm 3.4\%$  to  $\pm 6.3\%$  for NPV. At an interim analysis of clinical event rates, the incidence of septic shock was substantially lower than anticipated. We decided by consensus to change the primary outcome to severe sepsis (and subsequently adopted the sepsis-3 sepsis criteria[1] of Sequential Organ Failure Assessment (SOFA) score  $\geq 2$ ), with critical care admission a key secondary outcome, to ensure adequate clinically relevant events in the discriminant analyses. These changes occurred *prior to* study completion and were reported in the published protocol[8].

## Statistical analysis

The primary study cohort was cohort-1. The primary exposure was suspected infection. The cohorts-2 and 3 were comparator populations for cross-cohort discrimination and biomarker selection.

## Outcomes

The primary outcome was sepsis, defined as SOFA score  $\geq 2$  at 24 hours and/or 72 hours following presentation to hospital in patients with suspected infection in the ED (cohort-1)[1]. Secondary outcomes were: critical care admission or death within 72 hours of presentation; SOFA  $\geq 4$  at 24 hours and/or 72 hours following presentation to hospital; development of septic shock; discharge home within 72 hours; discharge to home or in hospital with no organ failure within 72 hours; death from sepsis;

confirmed infection and length of hospital stay[8]. All cohort-1 data are based on blood samples taken in the ED after recruitment.

### **Biomarkers selection strategy**

Our analytic approach to discover biomarkers with potential diagnostic discrimination for risk of subsequent sepsis occurred in three *a priori* planned stages, and one *post-hoc* analysis.

#### **Stage one: reliability**

Inter- and intra-reader reliability for 47 different biomarkers was established according to the protocol[8]. To be included in subsequent evaluation stages biomarkers needed to demonstrate both inter- and intra-reader reliability at the pre-defined intra-class correlation coefficient (ICC) between readers  $\geq 0.9$ ; see Figure-1 and eMethods-2; eTable-2). For intra-reader reliability the ICC for each reader was calculated as the ratio of within-reader variability to the total variance (within-reader plus residual variance) from the normal linear mixed model. For inter-reader reliability the ICC was calculated as the ratio of between-reader variability to the total variance (between-reader plus residual variance) from the normal linear mixed model. Reliability analyses were done prior to linking leukocyte biomarkers data and clinical outcome data.

#### **Stage two: cross-cohort discrimination**

For reliable biomarkers, statistically significant inter-group differences between the three cohorts were explored using Kruskal-Wallis analysis of variance (ANOVA) tests (eTable-3) and visual inspection of data. Biomarkers that discriminated between cohort-1 and either cohort-2 (true-positive) and/or cohort-3 (true negative) and had variability within cohort-1 consistent with potential to discriminate clinical outcomes were selected for Stage-3 analysis. Other factors considered were cell counts, the

magnitude of MFI, and potential linkage and co-linearity between groups of biomarkers. This was done in consensus meetings by researchers blinded from clinical outcomes within cohort-1.

### **Stage three: Prediction of clinical outcomes in cohort-1**

Within cohort-1 patients, the ability of the selected biomarkers to predict the primary and secondary outcomes was calculated using univariate logistic regression. For the secondary outcomes of death from sepsis, septic shock and length of stay, we provided a descriptive summary as per the analysis plan[8]. The odds ratio (OR) for the outcome per standard deviation increase in biomarker, Receiver Operating Characteristic (ROC) curves, and area under ROC curve (AUROC) were used to assess predictive ability. Youden's index identified the optimal cut-off point for each marker[13]. Candidate biomarkers that showed consistent inclusion were then taken forward for multivariable modelling.

We used best subsets regression[14] to identify optimal combinations of predictive markers. Specifically, models containing a given number of biomarkers were fitted for all potential biomarker combinations. The five best-fitting models of a given size, according to the chi-squared score statistic, were identified. Biomarkers which consistently appeared in the best-fitting models were selected for the final model. The change in chi-squared score statistic between the best fitting models containing different numbers of biomarkers was used to determine the number of biomarkers to be included in the final model. Linearity of biomarker associations on the logistic scale was checked using plots of deviance residuals. Based on consistency and model fit we identified optimal combinations of predictive markers.

## Post hoc extreme phenotype comparison

On the recommendation of a pre-planned independent expert group (see eTable-4), we compared biomarker profiles between sub-populations within cohort-1 with extreme clinical phenotypes of organ dysfunction and outcome to further explore associations for the biomarkers evaluated. We defined *well* and *sick* extreme phenotypes[7], by consensus among clinical investigators using clinical data without knowledge of group differences in biomarkers (eFigure-2). The *well* phenotype had no positive microbiology, a SOFA score  $\leq 2$  at 24 *and* 72 hours post-enrolment and were either discharged home by 72 hours or were in hospital but no longer receiving antibiotics. The *sick* phenotype had a confirmed infection, SOFA score  $\geq 2$  at both 24 *and* 72 hours post-enrolment and were still in hospital and receiving antibiotics at 72 hours. We compared biomarker expression between the two phenotypes using two-sample t-tests or Mann Whitney tests as appropriate, applying Bonferroni correction for multiple testing.

For additional comparison, we also measured C-reactive protein (CRP) and Procalcitonin (PCT) concentrations at the same time point for Cohort-1 patients, given the widespread clinical use of these biomarkers in assessing infection. We constructed ROC curves for CRP and PCT and estimated similar univariate predictive performance characteristics of these for outcomes reported, to enable direct comparison of predictive validity with the more novel biomarkers.

## Results

### Patient characteristics

Between January 2014 and February 2016, we recruited 272, 59 and 75 patients (N=406) to cohorts 1, 2, and 3 respectively. The clinical characteristics for the three

cohorts and the cohort-1 outcomes are shown in Table-1. Cohorts-1 and 3 had a similar age and sex distribution. Cohort-2 patients tended to be older. The primary outcome in cohort-1, clinical deterioration to sepsis, occurred in 139 patients (51.1%).

### **Stage one: Reliability**

The step-wise assessment of intra-reader and then inter-reader reliability resulted in rejection of 14 biomarkers as non-reliable, leaving 33 reliable biomarkers for cross-cohort comparison (Figure-1; eTable-2).

### **Stage two: Cross-cohort discrimination**

Statistical comparison, expert review, and cohort-1 data distribution resulted in rejection of a further 17 biomarkers (Figure-1; eTable-2; eTable-3). The cross-cohort comparisons plots for the 16 selected biomarkers are shown in eFigure-3. Based on the stage-1 and two selections, eight neutrophil biomarkers (cluster of differentiation antigens (CD) CD15;CD24;CD35;CD64;CD312;CD11b;CD274;CD279), seven monocyte biomarkers (CD35;CD64;CD312;CD11b;HLA-DR;CD274;CD279) and one CD8 T-lymphocyte biomarker (CD279) were selected for evaluation of discrimination for clinical outcomes. Biological relevance of these markers in sepsis are summarized in Table-2.

### **Stage three: Prediction of clinical outcomes in cohort-1**

Most biomarkers lacked any clinically or statistically significant discrimination for predicting primary and secondary outcomes within cohort-1 patients. Amongst the individual biomarkers, clinical deterioration to sepsis was associated with higher neutrophil CD279 expression, higher monocyte CD279 expression and lower monocyte HLA-DR expression. The optimal MFI cut off for neutrophil CD279 was 239 (sensitivity 0.88 (95% confidence interval:0.82 – 0.93); specificity 0.35(0.26 –

0.43); for monocyte CD279 was 141 (sensitivity 0.83(0.77 – 0.90); specificity 0.39(0.30 – 0.47); and for monocyte HLA-DR was 3572 (sensitivity 0.43(0.34 – 0.51); specificity 0.69(0.60 – 0.77). Although these associations were statistically significant, discriminant ability was poor and unlikely to be clinically useful in isolation.

With best subsets logistic regression, the optimum combination for predicting clinical deterioration to sepsis included increased neutrophil CD24; increased neutrophil CD279; and reduced monocyte HLA-DR expression (sensitivity 0.72(0.64 – 0.79); specificity 0.56(0.48 – 0.65). With best subsets logistic regression, the optimum combination for predicting the secondary outcome of discharge to home within 72 hours, included increased neutrophil CD15, reduced neutrophil CD274 and increased total monocyte HLA-DR expression. No biomarkers had significant discriminant value for the outcome of critical care admission or death within 72 hours. The performance of individual and optimized combinations of biomarkers for predicting the primary and secondary outcomes, are shown in Table-3. No marked non-linearities in biomarker effects were identified. Overall, although statistically significant associations were demonstrated, discrimination of clinical outcomes was unlikely to be clinically useful.

### **Extreme phenotype analysis**

From 272 patients in cohort-1, we identified 40 ‘well’ and 52 ‘sick’ phenotypes (eFigure-2). ‘Sick’ phenotype patients were characterized by being older, more often male, with a higher frequency of co-morbidities, more frequently lymphopenic, with higher APACHE II and SOFA scores at baseline. After Bonferroni correction for multiple comparisons, ‘sick’ phenotypes had significantly higher monocyte CD279



and neutrophil CD279 in the ED, but no other biomarkers were different (Table-3; eFigure-4).

For both CRP and PCT, there was also no statistically or clinically significant discrimination for subsequent sepsis with univariate analysis (Table-3).

## Discussion

In this multi-site cohort study, we reduced a candidate panel of 47 leukocyte biomarkers to 16 reliable biomarkers with potential for discriminating the risk of developing sepsis in patients with suspected infection presenting to the ED. The combination of higher neutrophil CD24, higher neutrophil CD279, and a lower monocyte HLA-DR expression best predicted the clinical deterioration to sepsis. Consistent with this association, a lower neutrophil CD279 expression and higher monocyte HLA-DR expression were associated with discharge home within 72 hours (implying rapid recovery). Although our pre-defined biomarker discovery strategy identified these biomarkers as associated with development of sepsis and more severe illness, their discriminant value was insufficient to suggest utility for decision-making in routine clinical care.

Our findings have potential clinical relevance. The key pathophysiological insight is that leukocyte biomarkers of immunosuppression such as check-point inhibitors (CD279; CD274) and antigen processing ability (HLA-DR) were altered even in patients with *suspected infection* presenting to ED. We also demonstrate the importance of assessing reliability when standardising flow cytometry for large-scale time critical use. The development of clinically useable tests is likely to require a form of cross-platform calibration (such as multiparametric version of the Quantibrite system, BD Bioscience). Our study shows it is feasible to implement flow cytometry

as a means of undertaking precision medicine in sepsis, for example to guide novel therapeutic interventions such as those tested recently in immunotherapy trials [15] and highlighted in recent expert reviews [16, 17]. However, our data suggest that for patients with suspected infection the predictive validity of panels of leukocyte biomarkers are unlikely to be useful as general clinical decision-making tools. Of note, both CRP and PCT also performed poorly.

Strengths of our study were well-defined hypothesis, pre-published protocol [8], internationally accepted primary outcome [1], clinically relevant secondary outcomes and hierarchical analytic approach to reduce biomarker selection bias. Reliability of multi-site flow cytometry is potentially problematic due to measurement error bias [18], which we addressed rigorously with fluorochrome-conjugated antibody titrated for optimal signal and kept constant throughout the study. Using hospitalized non-infected patients and ICU-sepsis patients as comparators during biomarker selection increased the chance of detecting infection related host responses and is superior to using healthy volunteer controls. Our blood sampling time point in the ED was prior to severe illness, before major clinical interventions, and much earlier than in previous studies of sepsis biomarkers, and we excluded patients who clinicians considered already had established sepsis and/or critical illness. As such our population was different from other recent studies, which evaluated leukocyte biomarkers for prediction of sepsis trajectory (by including patients with sepsis-2 defined sepsis, severe sepsis and septic shock) [19, 20] and stratified nosocomial infection risk in ICU patients[21] (see eTable-5 that highlights important differences). The post-hoc extreme phenotype analysis enhanced face validity by considering multiple clinical variables simultaneously for phenotype definition.

Our study has potential weaknesses. Although we could not include all potential leukocyte biomarkers, we studied a range of leukocyte biomarkers (such as complement pathway receptors (CD35, CD11b), G protein-coupled receptors (CD312), Fc-gamma-receptors (CD64[22, 23]), factors delaying neutrophil apoptosis (CD24[22]), check-point molecules (CD274, CD279)[24]; HLA-DR expression [25-27]), that previous studies highlight association with adverse outcomes in established sepsis. We enrolled a smaller sample size than planned due to time and funding constraints. However, this had a limited impact since substantial differences in biomarker levels across cohorts still enabled selection of candidate biomarkers for further discriminant analysis. Supervised classification methods such as classification and regression trees (CART) is a valid alternative analytic approach for this research question. However, CART requires approximately 50 events per variable when predicting a dichotomised outcome, before predictions become stable and over-optimism is minimised [28]. As our observed number of sepsis events did not reach this threshold we opted to use the best subsets logistic regression approach as pre-specified in our statistical analysis plan [8]. As our cohort-1 inclusion criteria mandated SIRS, we have excluded SIRS negative patients with infection, who could have progressed to develop sepsis. However, this is unlikely to bias the results, as the prevalence of SIRS negative sepsis-3 sepsis in ICUs in England is only 3% [29]. As our objective was to study leukocyte biomarkers at an earlier time point than previously achieved and to identify biomarkers that predict deterioration within 72 hours of hospitalisation, we excluded patients planned for direct admission to ICU from the ED at enrolment, which explains the lower than expected event rate for death and septic shock. Findings might be different for more

severely ill patients studied later in sepsis, as observed in other recent flowcytometric studies (eTable-5) [19-21].

Our findings have biological plausibility, as the leukocyte biomarkers that best predicted the risk of developing sepsis in our study were on the key innate immune cells, namely neutrophils and monocytes, which are first responders to infection. The strongest biomarker predicting subsequent sepsis and extreme phenotypes was higher levels of CD279 (programmed death receptor 1, PD-1) on monocytes and neutrophils. CD279 expression is associated with neutrophil and monocyte suppressor subsets [30], memory lymphocyte subsets [31], is thought to regulate T-cell responses and induce an inhibitory signal characterized by cell cycle arrest and reduced cytokine synthesis [2, 32]. This early role for CD279/PD-1 is consistent with animal models of sepsis [33] and sepsis cohorts [30]. CD279/PD-1 act in conjunction with its ligand CD274 (PD-L1). In our study, lower CD274, together with lower CD279, higher monocyte HLA-DR, and lower neutrophil CD24, emerged as a predictor for rapid recovery sepsis phenotype. These novel findings require further confirmatory studies.

Although none of the biomarkers we studied had discriminant ability that could be used to guide clinical decision-making, our data implies that immunosuppression in infected patients precedes established sepsis and that higher CD279/PD-1 and lower HLA-DR are potential theragnostic and enrichment markers [34-37] for anti-PD-1/PDL-1 agents and granulocyte-monocyte colony stimulating factor[25] respectively, for carefully designed immunotherapy trials [3, 38].

## Conclusions

We conclude that in a population of patients presenting with suspected infection, prior to established sepsis, a sequential approach to identifying reliable potential leukocyte biomarkers from a large candidate panel that may predict the subsequent development of sepsis identified only a small number with discriminant properties. These were markers of immune suppression, namely CD279 and HLA-DR, suggesting this may be an early event, prior to development of sepsis.

### **Acknowledgements:**

This independent research by Dr Manu Shankar-Hari is supported by the National Institute for Health Research Clinician Scientist Award (NIHR-CS-2016-16-011). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health.

Prof Christopher Weir was supported in this work by NHS Lothian via the Edinburgh Clinical Trials Unit.

Dr Andrew Conway Morris is supported by a Clinical Research Career Development Fellowship from the Wellcome Trust (WT 2055214/Z/16/Z)

## References

1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC, (2016) The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA* 315: 801-810
2. Hotchkiss RS, Monneret G, Payen D, (2013) Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. *Nat Rev Immunol* 13: 862-874
3. van der Poll T, van de Veerdonk FL, Scicluna BP, Netea MG, (2017) The immunopathology of sepsis and potential therapeutic targets. *Nat Rev Immunol* 17: 407-420
4. Scicluna BP, van Vught LA, Zwinderman AH, Wiewel MA, Davenport EE, Burnham KL, Nurnberg P, Schultz MJ, Horn J, Cremer OL, Bonten MJ, Hinds CJ, Wong HR, Knight JC, van der Poll T, consortium M, (2017) Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study. *The Lancet Respiratory medicine* 5: 816-826
5. Venet F, Guignant C, Monneret G, (2011) Flow cytometry developments and perspectives in clinical studies: examples in ICU patients. *Methods Mol Biol* 761: 261-275
6. Angus DC, Seymour CW, Coopersmith CM, Deutschman CS, Klompas M, Levy MM, Martin GS, Osborn TM, Rhee C, Watson RS, (2016) A Framework for the Development and Interpretation of Different Sepsis Definitions and Clinical Criteria. *Crit Care Med* 44: e113-121

7. Shankar-Hari M, (2017) How could we enhance translation of sepsis immunology to inform immunomodulation trials in sepsis? Crit Care 21: 125
8. Datta D, Conway Morris A, Antonelli J, Warner N, Brown KA, Wright J, Simpson AJ, Rennie J, Hulme G, Lewis SM, Mare TA, Cookson S, Weir CJ, Dimmick I, Keenan J, Rossi AG, Shankar-Hari M, Walsh TS, Ex PSI, (2016) Early PREdiction of Severe Sepsis (ExPRES-Sepsis) study: protocol for an observational derivation study to discover potential leucocyte cell surface biomarkers. BMJ Open 6: e011335
9. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G, Sccm/Esicm/Accp/Ats/Sis, (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31: 1250-1256
10. Shankar-Hari M, Phillips GS, Levy ML, Seymour CW, Liu VX, Deutschman CS, Angus DC, Rubenfeld GD, Singer M, Sepsis Definitions Task F, (2016) Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315: 775-787
11. Gray A, Ward K, Lees F, Dewar C, Dickie S, McGuffie C, committee Ss, (2013) The epidemiology of adults with severe sepsis and septic shock in Scottish emergency departments. Emerg Med J 30: 397-401
12. Glickman SW, Cairns CB, Otero RM, Woods CW, Tsalik EL, Langley RJ, van Velkinburgh JC, Park LP, Glickman LT, Fowler VG, Jr., Kingsmore SF, Rivers EP, (2010) Disease progression in hemodynamically stable patients presenting to the emergency department with sepsis. Acad Emerg Med 17: 383-390



13. Fluss R, Faraggi D, Reiser B, (2005) Estimation of the Youden Index and its associated cutoff point. *Biometrical journal Biometrische Zeitschrift* 47: 458-472
14. Miller, A., Tibshirani, R., Cox, D., Keiding, N., Isham, V., Louis, T., Tong, H., Reid, N. (2002). *Subset Selection in Regression*. New York: Chapman and Hall/CRC.
15. Francois B, Jeannet R, Daix T, Walton AH, Shotwell MS, Unsinger J, Monneret G, Rimmele T, Blood T, Morre M, Gregoire A, Mayo GA, Blood J, Durum SK, Sherwood ER, Hotchkiss RS, (2018) Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial. *JCI insight* 3
16. Perner A, Gordon AC, Angus DC, Lamontagne F, Machado F, Russell JA, Timsit JF, Marshall JC, Myburgh J, Shankar-Hari M, Singer M, (2017) The intensive care medicine research agenda on septic shock. *Intensive Care Med*: 1-12
17. Perner A, Rhodes A, Venkatesh B, Angus DC, Martin-loeches I, Preiser J-C, Vincent J-L, Marshall J, Reinhart K, Joannidis M, Opal SM, (2017) Sepsis: frontiers in supportive care, organisation and research. *Intensive Care Med*: 1-13
18. Mittag A, Tarnok A, (2009) Basics of standardization and calibration in cytometry--a review. *Journal of biophotonics* 2: 470-481
19. Daix T, Guerin E, Tavernier E, Mercier E, Gissot V, Herault O, Mira JP, Dumas F, Chapuis N, Guitton C, Bene MC, Quenot JP, Tissier C, Guy J, Piton G, Roggy A, Muller G, Legac E, de Prost N, Khellaf M, Wagner-Ballon O, Coudroy R, Dindinaud E, Uhel F, Roussel M, Lafon T, Jeannet R, Vargas F, Fleureau C, Roux M, Allou K, Vignon P, Feuillard J, Francois B, (2018)

Multicentric Standardized Flow Cytometry Routine Assessment of Patients  
With Sepsis to Predict Clinical Worsening. Chest

20. Guerin E, Orabona M, Raquil MA, Giraudeau B, Bellier R, Gibot S, Bene MC, Lacombe F, Droin N, Solary E, Vignon P, Feuillard J, Francois B, (2014) Circulating immature granulocytes with T-cell killing functions predict sepsis deterioration\*. Crit Care Med 42: 2007-2018
21. Conway Morris A, Datta D, Shankar-Hari M, Stephen J, Weir CJ, Rennie J, Antonelli J, Bateman A, Warner N, Judge K, Keenan J, Wang A, Burpee T, Brown KA, Lewis SM, Mare T, Roy AI, Hulme G, Dimmick I, Rossi AG, Simpson AJ, Walsh TS, (2018) Cell-surface signatures of immune dysfunction risk-stratify critically ill patients: INFECT study. Intensive Care Med 44: 627-635
22. Parlato M, Souza-Fonseca-Guimaraes F, Philippart F, Misset B, Captain Study G, Adib-Conquy M, Cavaillon JM, (2014) CD24-triggered caspase-dependent apoptosis via mitochondrial membrane depolarization and reactive oxygen species production of human neutrophils is impaired in sepsis. J Immunol 192: 2449-2459
23. Gros A, Roussel M, Sauvadet E, Gacouin A, Marque S, Chimot L, Lavoue S, Camus C, Fest T, Le Tulzo Y, (2012) The sensitivity of neutrophil CD64 expression as a biomarker of bacterial infection is low in critically ill patients. Intensive Care Med 38: 445-452
24. Chang K, Svabek C, Vazquez-Guillamet C, Sato B, Rasche D, Wilson S, Robbins P, Ulbrandt N, Suzich J, Green J, Patera AC, Blair W, Krishnan S, Hotchkiss R, (2014) Targeting the programmed cell death 1: programmed cell

death ligand 1 pathway reverses T cell exhaustion in patients with sepsis. Crit Care 18: R3

25. Meisel C, Schefold JC, Pschowski R, Baumann T, Hetzger K, Gregor J, Weber-Carstens S, Hasper D, Keh D, Zuckermann H, Reinke P, Volk HD, (2009) Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 180: 640-648
26. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP, (1995) The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 273: 117-123
27. Rangel-Frausto MS, Pittet D, Hwang T, Woolson RF, Wenzel RP, (1998) The dynamics of disease progression in sepsis: Markov modeling describing the natural history and the likely impact of effective antisepsis agents. Clin Infect Dis 27: 185-190
28. van der Ploeg T, Austin PC, Steyerberg EW, (2014) Modern modelling techniques are data hungry: a simulation study for predicting dichotomous endpoints. BMC Med Res Methodol 14: 137
29. Shankar-Hari M, Harrison DA, Rowan KM, (2016) Differences in Impact of Definitional Elements on Mortality Precludes International Comparisons of Sepsis Epidemiology-A Cohort Study Illustrating the Need for Standardized Reporting. Crit Care Med 44: 2223-2230
30. Patera AC, Drewry AM, Chang K, Beiter ER, Osborne D, Hotchkiss RS, (2016) Frontline Science: Defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1. J Leukoc Biol 100: 1239-1254

31. Wilson JK, Zhao Y, Singer M, Spencer J, Shankar-Hari M, (2018) Lymphocyte subset expression and serum concentrations of PD-1/PD-L1 in sepsis - pilot study. *Crit Care* 22: 95
32. Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, Bricker TL, Jarman SD, 2nd, Kreisel D, Krupnick AS, Srivastava A, Swanson PE, Green JM, Hotchkiss RS, (2011) Immunosuppression in patients who die of sepsis and multiple organ failure. *JAMA* 306: 2594-2605
33. Wang JF, Li JB, Zhao YJ, Yi WJ, Bian JJ, Wan XJ, Zhu KM, Deng XM, (2015) Up-regulation of programmed cell death 1 ligand 1 on neutrophils may be involved in sepsis-induced immunosuppression: an animal study and a prospective case-control study. *Anesthesiology* 122: 852-863
34. Pene F, Courtine E, Cariou A, Mira JP, (2009) Toward theragnostics. *Crit Care Med* 37: S50-58
35. Shankar-Hari M, Rubenfeld GD, (2017) The use of enrichment to reduce statistically indeterminate or negative trials in critical care. *Anaesthesia* 72: 560-565
36. Prescott HC, Calfee CS, Thompson BT, Angus DC, Liu VX, (2016) Toward Smarter Lumping and Smarter Splitting: Rethinking Strategies for Sepsis and Acute Respiratory Distress Syndrome Clinical Trial Design. *Am J Respir Crit Care Med* 194: 147-155
37. Hotchkiss RS, Sherwood ER, (2015) Immunology. Getting sepsis therapy right. *Science* 347: 1201-1202
38. Venet F, Monneret G, (2018) Advances in the understanding and treatment of sepsis-induced immunosuppression. *Nat Rev Nephrol* 14: 121-137

39. Parlato M, Souza-Fonseca-Guimaraes F, Philippart F, Misset B, Adib-Conquy M, Cavaillon JM, (2014) CD24-triggered caspase-dependent apoptosis via mitochondrial membrane depolarization and reactive oxygen species production of human neutrophils is impaired in sepsis. *J Immunol* 192: 2449-2459
40. Jalava-Karvinen P, Hohenthal U, Laitinen I, Kotilainen P, Rajamaki A, Nikoskelainen J, Lilius EM, Nuutila J, (2009) Simultaneous quantitative analysis of Fc gamma RI (CD64) and CR1 (CD35) on neutrophils in distinguishing between bacterial infections, viral infections, and inflammatory diseases. *Clin Immunol* 133: 314-323
41. Wang X, Li ZY, Zeng L, Zhang AQ, Pan W, Gu W, Jiang JX, (2015) Neutrophil CD64 expression as a diagnostic marker for sepsis in adult patients: a meta-analysis. *Crit Care* 19: 245
42. Lewis SM, Treacher DF, Edgeworth J, Mahalingam G, Brown CS, Mare TA, Stacey M, Beale R, Brown KA, (2015) Expression of CD11c and EMR2 on neutrophils: potential diagnostic biomarkers for sepsis and systemic inflammation. *Clin Exp Immunol* 182: 184-194
43. Netea MG, Balkwill F, Chonchol M, Cominelli F, Donath MY, Giamarellos-Bourboulis EJ, Golenbock D, Gresnigt MS, Heneka MT, Hoffman HM, Hotchkiss R, Joosten LAB, Kastner DL, Korte M, Latz E, Libby P, Mandrup-Poulsen T, Mantovani A, Mills KHG, Nowak KL, O'Neill LA, Pickkers P, van der Poll T, Ridker PM, Schalkwijk J, Schwartz DA, Siegmund B, Steer CJ, Tilg H, van der Meer JWM, van de Veerdonk FL, Dinarello CA, (2017) A guiding map for inflammation. *Nat Immunol* 18: 826-831

44. Pillay J, Kamp VM, van Hoffen E, Visser T, Tak T, Lammers JW, Ulfman LH, Leenen LP, Pickkers P, Koenderman L, (2012) A subset of neutrophils in human systemic inflammation inhibits T cell responses through Mac-1. *J Clin Invest* 122: 327-336
45. Pillay J, Tak T, Kamp VM, Koenderman L, (2013) Immune suppression by neutrophils and granulocytic myeloid-derived suppressor cells: similarities and differences. *Cell Mol Life Sci* 70: 3813-3827
46. Mare TA, Treacher DF, Shankar-Hari M, Beale R, Lewis SM, Chambers DJ, Brown KA, (2015) The diagnostic and prognostic significance of monitoring blood levels of immature neutrophils in patients with systemic inflammation. *Crit Care* 19: 57
47. Jamsa J, Huotari V, Savolainen ER, Syrjala H, Ala-Kokko T, (2015) Kinetics of leukocyte CD11b and CD64 expression in severe sepsis and non-infectious critical care patients. *Acta Anaesthesiol Scand* 59: 881-891
48. Brunialti MK, Martins PS, Barbosa de Carvalho H, Machado FR, Barbosa LM, Salomao R, (2006) TLR2, TLR4, CD14, CD11B, and CD11C expressions on monocytes surface and cytokine production in patients with sepsis, severe sepsis, and septic shock. *Shock* 25: 351-357
49. Wagner C, Kotsougiani D, Pioch M, Prior B, Wentzensen A, Hansch GM, (2008) T lymphocytes in acute bacterial infection: increased prevalence of CD11b(+) cells in the peripheral blood and recruitment to the infected site. *Immunology* 125: 503-509
50. Demaret J, Venet F, Friggeri A, Cazalis MA, Plassais J, Jallades L, Malcus C, Poitevin-Later F, Textoris J, Lepape A, Monneret G, (2015) Marked alterations

of neutrophil functions during sepsis-induced immunosuppression. J Leukoc Biol

## TABLES

**Table-1: Cohort characteristics and outcomes**

	Cohort-1 (Infected ED cohort) N=272	Cohort-2 (ICU-septic) N=59	Cohort-3 (non-infected ED controls) N=75
<b>Cohort characteristics</b>			
Age in years mean (SD)	62.1 (19.1)	67.9 (12.8)	61.6 (20.0)
Female N (%)	133 (48.9%)	23 (39.0%)	33 (44.0%)
FCI Score Median (IQR)	2 (1,3)	2 (1,4)	1 (0,2)
White cell count Median (IQR)			
- Total	13.5 (10.7, 16.2)	16.9 (10.1, 19.6)	7.7 (6.4, 9.1)
- Neutrophils	11.2 ( 8.5, 14.1)	14.1 ( 8.2, 17.5)	4.9 (4.1, 6.4)
- Lymphocytes	0.9 ( 0.6, 1.4)	0.9 ( 0.6, 1.3)	1.7 (1.3, 2.1)
C-reactive protein Median (IQR)	64 (21,168)	212 (86,309)	13 (2,27)
Procalcitonin Median (IQR)	29.4 (0.0, 337.3)	No data	No data
Confirmed infection	238 (87.5%)	59 (100%)	0
qSOFA score $\geq 2$			
- at ED presentation	44 (16.2%)	No data	No data
- at 24 hours	6 ( 2.2%)		
- at 72 hours	5 ( 1.8%)		
APACHE II score Median (IQR)	9 (6,13)	16 (12,21)	6 (3,9)
SOFA score Median (IQR)	2 (1,3)	7 (5,9)	1 (1,2)
Site of infection N(%)			
- Respiratory	124 (45.6%)		
- Urinary	44 (16.2%)		
- Unknown	40 (14.7%)		
- Musculoskeletal, skin and soft tissue	32 (11.7%)		
- Abdominal (including biliary)	28 (11.0%)		
- Neurological	4 (1.5%)		
<b>Outcomes for Cohort-1</b>			
Primary outcome <sup>1</sup>			
- SOFA $\geq 2$ at 24 or 72 hours	139 (51.1%)		
Secondary outcomes			
- ICU admission or death within 72 hours of hospitalization	22 (8.1%)		
- SOFA $\geq 4$ at 24 or 72 hours	36 (13.2%)		
- Discharged home within 72 hours of hospitalization	86 (31.6%)		
- Discharged home or in hospital with no organ failure	148 (54.4%)		
- Hospital mortality N (%)	1 (0.4%)		
- Development of septic shock	1 (0.4%)		
Organ support			
- On antibiotics at 72 hours	144 (52.9%)		
- Vasopressors	2 (0.7%)		
- Ventilation invasive	2 (0.7%)		
- Ventilation non-invasive	5 (1.8%)		
Hospital length of stay (days) Median (IQR)	5 (2, 9)		



**Table-2: Biological relevance in sepsis patients of the reliable cell surface markers with discriminant value identified in Cohort-1**


Cell surface markers	Marker positive leukocytes in our study	Biological relevance in sepsis[2, 3, 25, 32, 39-43]	Our key inferences
CD15	Neutrophil	Expressed on all myeloid cells and from the promyelocyte stage onwards on neutrophils. Although monocytes express CD15 at low levels, we were gating CD15 <sup>hi</sup> granulocytes.	Alongside CD14, CD16, CD11b, CD15, is a marker for myeloid derived suppressor cells[44, 45], which is implicated in suppressing T cell function.
CD24	Neutrophil	Expressed on mature granulocytes and B cells; down-regulated on neutrophils in sepsis, induces neutrophil apoptosis which is delayed in sepsis.	CD16 low/CD14 negative / CD24 positive myeloid-derived suppressor cells are cytotoxic to T cells[20]. Immature granulocytes in peripheral circulation in sepsis is associated with greater risk of death[46].
CD35	Neutrophil Monocytes	Receptors of complement activation (RCA) family expressed on leukocytes; potentially discriminates sepsis from inflammation	Understanding of major roles of CD35 alterations in sepsis is unclear.
CD64	Neutrophil Monocytes	Fc gamma receptor expressed on leukocytes; Patients with sepsis have increased expression of CD64 has been consistently reported.	Despite this association, CD64 as a single marker has limited diagnostic performance in sepsis [23, 41].
CD11b	Neutrophil Monocytes	Role in adhesive interactions of monocytes, macrophages and granulocytes; mediating the uptake of complement-coated particles; increased in sepsis following neutrophil activation	Neutrophil and monocyte increase in CD11b is inconsistent in the literature[47, 48]. Tissue resident CD11b positive T cells, secrete interferon gamma and may influence local host defence mechanisms in bacterial infections[49].
CD312	Neutrophil Monocytes	human myeloid-restricted class B seven-span transmembrane (TM7) subfamily of G-protein coupled receptors; acutely altered in sepsis secondary to leukocyte activation	Understanding of major roles of CD312 alterations in sepsis is unclear.
CD274	Neutrophil Monocytes	PD-1 and PDL-1 form a check point inhibitor complex and are considered markers of sepsis related immunosuppression. In sepsis, neutrophils, monocytes and lymphocytes express elevated levels of with CD274 and CD279[2, 30, 31]. In sepsis, neutrophils are thought to impair T cell function through PD-L1 mechanism[33, 50].	Recently, it has been shown that the increasing functional deficit in multiple innate and adaptive immune responses in sepsis-related critical illness could be restored ex vivo in cells treatment with monoclonal antibodies targeting either arm of the PD-1:PD-L1 axis [30, 50]. Thus, measuring cellular levels of PD-1 and PD-L1 could inform trial design.
CD279	Neutrophil Monocytes CD-8 T cells		
HLA-DR	Monocyte	Consistently reported as a marker of immunosuppression in sepsis and in critically ill patients	Reduced HLA-DR expression on monocytes is associated with increased risk of nosocomial infection due to impaired monocyte competence. Monocyte HLA-DR expression less than 8000 monoclonal antibodies/cell for 2 or more days can be reversed with GM-CSF therapy, with potentially beneficial effects [25]. This is a useful biomarker for enrichment in future clinical trials.

**Table-2: Candidate biomarkers and combinations for predicting outcomes in cohort-1**

Biomarker	Marker expression in cohort-1 as Median MFI (IQR)	Primary outcome [OR (95% CI) per SD increase in MFI; p value]		Secondary outcomes <sup>1</sup> [OR (95% CI) per SD increase in MFI; p value]				
		SOFA score $\geq 2$ at 24 hours and/or 72 hours following presentation to hospital <sup>2</sup>	AUROC (95% CI)	ICU admission or death within 72 hours of presentation	SOFA $\geq 4$ at 24 or 72 hours after presentation	Discharge home within 72 hours of presentation	Discharge home within 72 hours of presentation or in-hospital with no organ failure	Confirmed infection
Neutrophils								
- CD15	31148 (22261, 39622)	0.94 (0.69 – 1.28); 0.70	0.50 (0.41 – 0.59)	1.36 (0.82 – 2.22); 0.23	1.01 (0.65 – 1.58); 0.97	1.38 (0.99 – 1.91); 0.06	1.13 (0.83 – 1.56); 0.42	0.89 (0.57, 1.41); 0.63
- CD24	22261 (16398, 28565)	1.20 (0.94 – 1.54); 0.15	0.56 (0.49 – 0.63)	1.26 (0.84 – 1.90); 0.17	1.48 (1.08 – 2.05); 0.01	1.00 (0.77 – 1.30); 1.00	0.79 (0.62 – 1.02); 0.07	1.31 (0.85, 2.04); 0.22
- CD35	17363 (10021, 26452)	0.98 (0.77 – 1.25); 0.87	0.51 (0.44 – 0.58)	1.18 (0.76 – 1.83); 0.45	0.90 (0.62 – 1.31); 0.59	1.18 (0.91 – 1.53); 0.21	1.15 (0.90 – 1.47); 0.28	1.34 (0.88, 2.06); 0.17
- CD64	2384 (1353, 5522)	0.95 (0.71 – 1.29); 0.75	0.49 (0.41 – 0.58)	0.98 (0.55 – 1.75); 0.94	0.88 (0.53 – 1.45); 0.61	0.97 (0.70 – 1.33); 0.83	0.95 (0.71 – 1.28); 0.74	1.62 (0.84, 3.12); 0.15
- CD312	685 (451, 845)	1.29 (0.99 – 1.67); 0.06	0.57 (0.50 – 0.64)	0.74 (0.43 – 1.29); 0.29	0.82 (0.55 – 1.23); 0.34	0.79 (0.59 – 1.06); 0.12	0.85 (0.67 – 1.09); 0.21	1.10 (0.73, 1.67); 0.64
- CD11b	20583 (13210, 28737)	1.25 (0.97 – 1.62); 0.08	0.56 (0.49 – 0.63)	1.45 (0.97 – 2.16); 0.07	1.36 (0.98 – 1.60); 0.57	1.12 (0.86 – 1.45); 0.39	0.84 (0.66 – 1.08); 0.18	1.27 (0.83, 1.96); 0.27
- CD274	269 (207, 320)	1.25 (0.96 – 1.61); 0.10	0.57 (0.50 – 0.64)	0.91 (0.55 – 1.49); 0.70	1.16 (0.83 – 1.61); 0.39	0.70 (0.51 – 0.95); 0.02	0.77 (0.59 – 0.99); 0.045	1.56 (0.97, 2.52); 0.07
- CD279	569 (300, 640)	1.78 (1.23 – 2.57); 0.002	0.59 (0.52 – 0.66)	0.96 (0.57 – 1.61); 0.86	1.06 (0.77 – 1.46); 0.72	0.57 (0.39 – 0.83); 0.003	0.60 (0.41 – 0.87); 0.007	1.06 (0.68, 1.66); 0.78
Monocyte								
- CD35	21018 (13818, 28565)	1.15 (0.89 – 1.48); 0.28	0.55 (0.48 – 0.62)	0.99 (0.62 – 1.57); 0.95	1.33 (0.97 – 1.83); 0.07	0.91 (0.70 – 1.20); 0.52	0.94 (0.73 – 1.20); 0.60	1.19 (0.77, 1.84); 0.44
- CD64	30848 (24499, 39622)	1.04 (0.77 – 1.39); 0.80	0.57 (0.49 – 0.66)	1.25 (0.77 – 2.03); 0.36	1.12 (0.74 – 1.71); 0.59	0.95 (0.69 – 1.30); 0.73	0.92 (0.69 – 1.24); 0.58	2.24 (1.11, 4.52); 0.02
- CD312	1087 (649, 1617)	0.91 (0.71 – 1.16); 0.43	0.54 (0.47 – 0.61)	0.73 (0.41 – 1.29); 0.29	0.79 (0.52 – 1.21); 0.28	1.24 (0.96 – 1.61); 0.09	1.06 (0.83 – 1.36); 0.64	0.94 (0.65, 1.36); 0.73
- CD11b	22705 (14413, 28651)	1.21 (0.94 – 1.57); 0.14	0.58 (0.51 – 0.65)	1.25 (0.83 – 1.88); 0.28	1.27 (0.91 – 1.76); 0.16	1.15 (0.89 – 1.49); 0.30	0.87 (0.68 – 1.12); 0.27	1.24 (0.80, 1.93); 0.33
- HLA-DR	4435 (2379, 8001)	0.73 (0.55 – 0.97); 0.03	0.56 (0.49 – 0.63)	0.69 (0.34 – 1.40); 0.30	0.76 (0.46 – 1.24); 0.27	1.35 (1.04 – 1.75); 0.02	1.34 (1.00 – 1.80); 0.052	0.96 (0.66, 1.38); 0.82
- CD274	60 (0, 166)	0.90 (0.70 – 1.16); 0.41	0.50 (0.43 – 0.56)	1.06 (0.69 – 1.61); 0.80	1.03 (0.73 – 1.46); 0.85	0.84 (0.62 – 1.15); 0.28	0.99 (0.78 – 1.27); 0.95	0.89 (0.64, 1.23); 0.48
- CD279	240 (129, 280)	1.32 (1.03 – 1.70); 0.03	0.58 (0.51 – 0.65)	0.89 (0.56 – 1.43); 0.31	1.21 (0.84 – 1.75); 0.27	0.68 (0.52 – 0.90); 0.006	0.80 (0.62 – 1.02); 0.07	0.98 (0.67, 1.44); 0.92
CD8 T cells	117 (72, 169)							
- CD279		1.16 (0.81 – 1.66); 0.43	0.48 (0.41 – 0.55)	0.23 (0.02 – 2.29); 0.21	0.94 (0.58 – 1.93); 0.80	0.79 (0.43 – 1.45); 0.45	0.82 (0.55 – 1.23); 0.34	2.00 (0.44, 9.06); 0.37
Neutrophil CD24 + Neutrophil CD279		1.48 (1.10 – 1.98); 0.009 2.23 (1.47 – 3.38); <0.001	0.64 (0.58 – 0.71)	*	*		0.65 (0.49 – 0.87); 0.004 0.47 (0.31 – 0.71); 0.0004	*
Neutrophil CD24 + Neutrophil CD279 + Monocyte HLA-DR		1.49 (1.10 – 2.00); 0.009 2.37 (1.54 – 3.64); <0.001 0.72 (0.53 – 0.97); 0.03	0.67 (0.60 – 0.74)			1.32 (0.94 – 1.85); 0.10 0.59 (0.41 – 0.86); 0.006 1.48 (1.03 – 2.13); 0.04		
Neutrophil CD15 + Neutrophil CD274 + Monocyte HLA-DR								
Other markers#								
CRP		1.20 (0.94 – 1.54); p=0.15	0.56 (0.49, 0.63)	0.88 (0.55 – 1.42); 0.60	0.99 (0.69 – 1.42); 0.94	0.74 (0.55 – 0.99); 0.04	0.85 (0.66 – 1.08); 0.19	1.16 (0.99 – 2.65); 0.06
PCT		0.94 (0.72 – 1.21); p=0.61	0.53 (0.46, 0.60)	0.93 (0.54 – 1.61); 0.57	0.81 (0.48 – 1.36); 0.42	0.83 (0.60 – 1.15); 0.27	1.02 (0.79 – 1.32); 0.89	4.00 (0.78 – 20.5); 0.10

**Table-4: Extreme phenotype description**

	Well phenotype (N = 40)	Sick phenotype (N = 52)	p-value
Age, median (IQR)	37.5 (27.3 – 56.8)	70.0 (56.0 – 81.0)	<0.001
Female, n (%)	26 (65%)	19 (37%)	0.009
FCI Score Median (IQR)	1 (0 – 2)	2 (1 – 3)	0.03
White cell count Median (IQR)			
Total	13.2 (10.3 – 14.4)	13.1 (9.1 – 16.5)	0.78
Neutrophils	10.3 (8.1 – 12.0)	11.2 (7.5 – 15.1)	0.29
Lymphocytes	1.2 (0.7 – 1.8)	0.8 (0.5 – 1.2)	0.01
C-reactive protein Median (IQR)	58.5 (24.0 – 107.3)	56.0 (16.5 – 191.0)	0.85
qSOFA score ≥2			
at ED presentation	3 (7.5%)	10 (19.2%)	0.11
at 24 hours	0	4 (7.7%)	0.07
at 72 hours	0	2 (3.8%)	0.22
Source of infection*, n (%)			
Respiratory	13 (40.6 %)	30 (57.7%)	0.13
Neurological	1 (3.1%)	2 (3.8%)	0.87
Urinary	2 (6.3 %)	7 (13.4%)	0.31
Abdominal	5 (15.6 %)	5 (9.6%)	0.41
Skin	9 (28.1 %)	3 (5.8%)	0.005
Biliary	0 (0%)	5 (9.6%)	0.005
Sepsis of unknown origin	2 (6.3 %)	0 (0%)	0.07
Baseline APACHE 2 score, median (IQR)	4.5 (2-7)	11.5 (9-16)	<0.001
Baseline SOFA, median (IQR)	1 (1-1)	3 (2-4)	<0.001
Discharged home within 72 hours, n (%)	32 (80%)	0	<0.001
Admitted to HDU/ICU within 72 hours, n (%)	0	14 (26.9%)	<0.001
Neutrophil biomarkers (MFI) median (IQR)			
Neutrophil CD15	30848 (24499 – 45352)	30848 (19116 – 41992)	>0.10
Neutrophil CD24	23815 (18299 – 29261)	24034 (18741 – 30710)	>0.10
Neutrophil CD35	19485 (7985 – 26580)	15636 (10988 – 25117)	>0.10
Neutrophil CD64	3098 (1528 – 6272)	2150 (1693 – 5378)	>0.10
Neutrophil CD312	565.8 (382.7 – 712.9)	670.9 (493.6 – 853.9)	>0.10
Neutrophil CD11b	16089 (13664 – 25552)	22154 (13510 – 30737)	>0.10
Neutrophil CD27s	279.0 (101.4 – 322.8)	284.3 (233.8 – 327.7)	>0.10
Neutrophil CD279	326.4 (152.7 – 584.2)	584.2 (383.7 – 648.8)	<b>0.005</b>
Monocyte biomarkers (MFI) median (IQR)			
Monocyte CD35	16556 (9974 – 27488)	22476 (15067 – 27681)	>0.10
Monocyte CD64	29685 (21843 – 45021)	33323 (29405 – 45352)	>0.10
Monocyte CD312	1243 (694 – 2001)	817.0 (470.5 – 1560.0)	>0.10
Monocyte CD11b	20205 (12102 – 26644)	26660 (16984 – 32741)	>0.10
Monocyte CD274	50.7 (0 – 167.2)	78.6 (0 – 199.7)	>0.10
Monocyte CD279	151.2 (94.8 – 262.1)	245.4 (161.1 – 287.0)	<b>0.05</b>
Monocyte HLA-DR	6172 (3516 – 11544)	4016 (2692 – 7170)	0.12
CD-8 T cell biomarker (MFI) median (IQR)			
CD8 T-Lymphocyte CD279	112.2 (78.7 – 153.3)	115.6 (58.5 – 167.9)	>0.10



## Online only supplement

### Shankar-Hari M et al. Early PREdiction of Sepsis using leucocyte cell surface biomarkers: The (ExPRES-Sepsis) cohort study

#### eMethods

**eMethods-1:** Detailed study cohort description<sup>1</sup> and description of gating with rationale

**eMethods-2:** Reliability and optimisation

#### eTables

**eTable-1:** Leukocyte biomarkers evaluated

MFI = mean fluorescence index; CD = Cluster of differentiation;

**eTable-2:** Table of Intraclass correlation coefficients (ICC) from the intra- and inter-rater reliability studies for each of the 47 biomarkers. Biomarkers rejected on intra-rater reliability testing are shown in red. Biomarkers rejected on inter-rater reliability testing are shown in blue

**eTable-3:** Rationale for Biomarkers selected for discriminant analysis in cross cohort comparison

**eTable-4:** Members of the independent expert review group who reviewed the provisional data from reliability, cross cohort comparisons, and discriminant analysis for the primary and secondary outcomes.

**eTable-5:** Comparison of recent leukocyte biomarker studies using multi-site flow cytometry with standardisation for illness trajectory prediction <sup>2-4</sup>

#### eFigures

**eFigure-1:** Flow diagram showing the decision analysis for assessing intra- and inter-rater reliability for the 47 biomarkers, and selecting biomarkers considered reliable for evaluation in cross cohort comparisons, as reported in the published protocol.

**eFigure-2:** Extreme phenotype derivation algorithm

**eFigure-3:** Cross cohort comparison of significant markers taken forward for further evaluation

**eFigure-4:** Comparison of biomarkers between sick phenotype, and well phenotypes

Shows significant differences in neutrophil CD279 between sick and well phenotype. MFI = Median Fluorescence intensity, reported on log10 scale. Statistical significance was determined using the Bonferroni-Dunn method to correct for multiple testing, with alpha = 0.05.

## **eMethods-1: Detailed study cohort description**

This was reported in the published protocol paper and is replicated here for completion<sup>1</sup>.

We recruited three distinct patient cohorts:

Cohort 1: Patients presenting to hospital with suspected infection with a systemic inflammation (discovery cohort).

Cohort 2: hospitalised patients with community-acquired severe sepsis requiring treatment in critical care (true- positive cohort).

Cohort 3: patients presenting with no suspicion of infection or systemic inflammation, needing hospitalisation ('non-sepsis comparison population').

### **Inclusion criteria**

#### **Cohort 1**

Age  $\geq 16$  years ( $\geq 18$  years in England), (2) SIRS criteria met, (3) clinical suspicion of sepsis (blood cultures and/ or other samples taken for microbial culture, or antibiotics started by clinical team), (4) no clinical suspicion of severe sepsis or septic shock at the time of enrolment and (5) enrolled within 12 hours of hospital (ED) presentation.

#### **Cohort 2**

Age  $\geq 16$  years ( $\geq 18$  years in England), (2) SIRS criteria met, (3) clinical suspicion of sepsis (blood cultures and/ or other samples taken for microbial culture, or antibiotics started by clinical team), (4) severity of sepsis requiring critical care admission (based on decision of caring clinical teams), (5) enrolled within 72 hours of hospital admission and (6) not enrolled into cohort 1 of ExPRES-Sepsis.

#### **Cohort 3**

Age  $\geq 16$  years ( $\geq 18$  years in England), (2) does not meet SIRS criteria, (3) no clinical suspicion of sepsis (blood cultures and/or other samples NOT taken for microbial culture, and antibiotics NOT started by clinical team), (4) patient expected to be admitted to hospital, (5) patient NOT expected to die during hospital admission.

### **Exclusion criteria (for all cohorts)**

Exclusions were chosen to ensure conditions that provoke a sterile inflammatory response or lead to immune dysfunction did not act as confounders during flow cytometry analysis. Patients who would not be actively treated were also excluded.


The exclusion criteria are any of: (1) acute pancreatitis, (2) haematological malignancy, (3) recent chemo- therapy (past 2 weeks), (4) myelodysplastic syndromes, (5) known neutropenia, (6) HIV infection, (7) viral hepatitis infection, (8) pregnancy, (9) blood transfusion  $>4$  units in past week, (10) oral corticosteroids for  $>24$  hours prior to enrolment, (11) decision not for active therapy/for palliative care at admission and (12) inability to consent the patient.

## **eMethods-1: Description of gating and rationale**

An a priori standard operating gating procedure was developed to identify other leukocyte biomarkers using the raw flow cytometry data. This involved: (1) initial strategy, based on pre-existing data, (2) expert learning and strategy refinement, to ensure ideal identification of leukocyte subtypes, and (3) expert consensus and finalisation of the gating strategy. These stages were undertaken iteratively by expert flow cytometrists (at least 2 years of flow cytometry experience) with cycles of testing and re-testing until a final procedure for each biomarker was agreed. We designed five separate panels.


## Panel-A

Marker	Fluorophore	Clone	Rationale/justification for use in the study
CD14	APC-H7	MΦP9	CD14 and CD15 have been chosen to help isolate monocytes and neutrophils. CD24, CD35, CD64 and CD312 have been chosen as markers of sepsis. Neutrophil CD64 is increased in infections. CD24 has been noted to be up regulated in in-vitro models of sepsis and blocking this pathway has been suggested to ameliorate sepsis. An increased CD312 (EMR2) expression on neutrophils has been linked with SIRS. An increase in CD35 expression has been linked to bacterial infection as compared to viral infection.
CD15	FITC	W6D3	
CD24	PerCP-Cy5.5	ML5	
CD35	PE	E11	
CD64	PE-Cy7	10.1	
CD312	AF647 (APC)	2A1 Serotec	



## Panel B


Marker	Fluorophore	Clone	Rationale/justification for use in the study
CD3	FITC	SK7	The strategy at looking at myeloid and plasmacytoid dendritic cells is based on previous studies and a commercial assay developed by BD Biosciences. CD3, CD19 and CD56 have been chosen, all on the FITC channel, as lineage selection markers to help gate for dendritic cells. CD11c and CD123 have been chosen to allow differentiation between dendritic cell subtypes. CD14 and CD16 have been chosen to detect monocyte subtypes. Low monocyte HLA-DR has been associated with poor outcome in sepsis.
CD11c	PerCP-Cy5.5	S.HCL-3	
CD14	APC-H7	MΦP9	
CD16	PE-Cy7	B73.1	
CD19	FITC	4G7	
CD56	FITC	NCAM16.2	
CD123	PE	9F5	
HLA-DR	APC	G46-6	






### Panel-C

Marker	Fluorophore	Clone	Rationale/justification for use in the study
CD9	PE	M-L13	CD11b and CD62L have been chosen to be investigated as markers of sepsis. CD11b expression is enhanced in neonatal sepsis. CD9, CD15 and CD16 have been chosen to explore neutrophil progenitors, as immature neutrophils are associated with worse outcomes in sepsis patients.
CD11b	PE-Cy7	ICRF 44	
CD15	FITC	W6D3	
CD16	APC-H7	3G8	
CD62L	APC	DREG-56	




### Panel-D

Marker	Fluorophore	Clone	Rationale/justification for use in the study
CD4	PerCp-Cy5.5	SK3	CD4 and CD8 have been chosen to differentiate between T-helper and cytotoxic T cells. CD14 and CD16 have been chosen to detect monocyte subtypes. CD274 (PD-L1) and CD279 (PD-1) are being assessed as potential markers of predicting sepsis, as increased expression is associated with worse outcomes in critically ill sepsis cohorts.
CD8	APC-H7	SK1	
CD14	FITC	MΦP9	
CD16	PE-Cy7	B73.1	
CD274	PE	MIH1	
CD279	APC	MIH4	



### Panel-E

Marker	Fluorophore	Clone	Rationale/justification for use in the study
CD3	FITC	SK7	CD3 detects lymphocyte, NK and NKT cell populations. CD56 has been chosen to detect NKT cells. CD335 has been chosen to detect NK cells. CD16, CD56 and CD57 have been chosen to detect NK cell subsets.
CD16	APC-H7	3G8	
CD56	PerCP-Cy5.5	B159	
CD57	APC	NK-1	
CD284	PE	T901	
CD335	PE-Cy7	p9E2/NKp46	



### Gating procedure

We evaluated stability of sample acquisition assessment by plotting time versus forward scatter and eliminated sections of poor flow. We then excluded cell aggregates using flow height versus area on the forward scatter. Further artefacts (debris) were eliminated by creating an “all cells” gate on the forward versus side scatter. Bi-exponential scaling was used for displaying and gating of flow cytometry data.

### Neutrophil biomarkers

1. Display CD15 vs SSC on the ‘all cells’ gate for granulocytes
2. Gate tightly on CD15<sup>hi</sup> for neutrophils
3. Determine MFI for true neutrophil population for CD14, CD15, CD24, CD35, CD64, and CD312

### Monocyte biomarkers

1. Display CD14 vs CD15 on all cells gate
2. Gate lymphocytes as CD14<sup>lo</sup> / CD15<sup>lo</sup>
3. Display FSC-A vs SSC-A on all cells gate
4. Gate for presumed monocytes by light scatter properties
5. Calculate true monocyte gate as “presumed monocytes” NOT lymphocytes NOT neutrophils
6. Display CD14 vs CD15 on true monocyte gate

- Plot 3 gates: total monocytes will be the largest rectangular gate, and 2 further gates: CD14<sup>hi</sup> monocytes and CD14<sup>lo</sup> monocytes
- Determine MFI for CD14, CD15, CD24, CD35, CD64, and CD312 markers on each monocyte population

#### ***Dendritic cells***

- Display Lin<sup>-</sup> (FITC-A) histogram on non-neutrophil gate (Note when referring to Lin<sup>-</sup> (lineage negative) we are referring to the CD3<sup>negative</sup> / CD19<sup>negative</sup> / CD56<sup>negative</sup> population.
- Gate for Lin<sup>-</sup> population using the marker tool - take the upper marker to the base of the Lin<sup>+</sup> population
- Display HLA-DR vs CD14 on the above Lin<sup>-</sup> subpopulation
- Gate HLA-DR<sup>positive</sup> / CD14<sup>negative</sup> sub-population using a square or polygon gate
- Display sub-population as CD16 vs SSC
- Gate for total dendritic cells (DCs) as CD16<sup>negative</sup> using a square gate
- Report total DCs as % of non-granulocyte cells
- Report MFI of HLA-DR on total DCs

#### ***Dendritic cell subsets***

- Display CD123 vs CD11c on the above total DCs
- Gate for myeloid dendritic cells as CD11c<sup>high</sup> / CD123<sup>low</sup>
- Gate for plasmacytoid dendritic cells as CD11c<sup>low</sup> / CD123<sup>high</sup>
- Gate for non-specific dendritic cells as CD11c<sup>low</sup> / CD123<sup>low</sup>
- Report DC subtypes as % of total DCs
- Report mDC as % of non-granulocytes

#### ***Neutrophil progenitors***

- Display neutrophil population for CD16 vs CD62L
- Gate the following neutrophil sub-types:
  - CD16<sup>hi</sup> as mature neutrophils
  - CD62L<sup>hi</sup> / CD16<sup>mid</sup> (as presumed late immature neutrophils)
  - CD62L<sup>lo</sup> / CD16<sup>lo</sup> (as early immature neutrophils)
- Record each gate as percentage of total granulocytes

#### ***Natural Killer T cells***

- Display CD3 vs CD56, on total lymphocytes
- Report NKT cells (CD3<sup>+</sup>/CD56<sup>+</sup>) as % of total lymphocytes

#### ***Natural Killer cells and subsets***

- Display CD3 vs CD335, on total lymphocytes
- Gate NK cells as CD3<sup>-</sup>/CD335<sup>+</sup>
- Report total NK cells as % of total lymphocytes
- NK subsets
  - Display CD16 vs CD56 on total NK cells
  - Gate naïve NK subset as CD56<sup>++</sup> / CD16<sup>-</sup>; report as % of total NK cells
  - Gate mature NK subset as CD56<sup>+</sup> / CD16<sup>+</sup>; report as % of total NK cells
  - Cytotoxic NK subset
    - Display histogram of CD57 on CD56<sup>+</sup> / CD16<sup>++</sup> mature NK subset (from previous step)
    - Report CD57<sup>high</sup> cytotoxic NK subset as % of mature NK cells (i.e. parent population)

## eMethods-2: Reliability and optimisation

### Sample size

Based on published recommendations<sup>5</sup>, a sample size of 50 files was selected for the measurement of inter-observer agreement, and 13 files were selected for intra-observer agreement. For intra-observer agreement each expert observer re-analysed a different set of 13 files. For inter-observer agreement three different readers analysed the same 50 files. All 47 biomarkers were read from each file. For the intra-observer agreement, the files were presented in random order to readers by an independent individual.

### Statistical testing of reproducibility

Each panel biomarker was assessed separately for intra- followed by inter-rater reliability. Reliability was assessed using intra-class correlation (ICC) coefficients and Bland-Altman plots. These measures were generated for both intra- and inter- observer agreement. ICC is expressed on a scale from 0 to 1: an ICC of 1.0 is interpreted as no variance between each observer, the ideal situation where observers can be considered interchangeable. An ICC cut-off of 0.9 was selected as the threshold for selection on the basis of previous literature. ICCs below this were judged to have inadequate reliability.

Analysis of each laboratory marker generated 3 intra-observer ICC coefficient statistics, describing the repeatability of reading by each observer. For inter-rater reliability each marker had 1 ICC coefficient statistic, describing the repeatability of the gating strategy across the 3 observers. Further assessment of each reader and each marker was performed using descriptive summary statistics and Bland-Altman statistics as required. Logarithmic transformation of data was carried out for further analyses if any data was not normally distributed. Bland-Altman plots were displayed as means vs differences, with the mean of differences referred to as bias, and upper and lower limits of agreements (U-LoA and L-LoA respectively) also generated.

### Interpretation of reliability statistics

A protocol and rules-based system was created *a priori* to interpret the results of the reliability study (Figure 1). Intra-observer reliability was assessed first; the rationale being that intra-rater reliability was essential before any comparison between readers was likely to have clinical utility in discriminant analysis. If intra-rater reliability was established, the analysis proceeded to inter-observer reliability analysis. We required biomarkers to demonstrate both intra- and inter-rater reliability in order to be taken to the cross-cohort comparisons.

The interpretation strategy was designed to allow re-examination of markers which might potentially be falsely excluded due to any single data points which might be outliers.

### Protocol for reliability assessment

#### Intra-observer reliability

##### Step 1

- a. Is the intra-observer ICC for all 3 observers is greater than or equal to 0.9?
- b. If yes, the outcome will be classified as having high reliability, and biomarker taken forward to the inter-observer interpretation stage
- c. If no, proceed to step 2

##### Step 2

- a. Do 2 out of 3 observers have an intra-observer ICC of greater than or equal to 0.9?
- b. If no, outcome classified as having low reliability, and biomarker not be taken forward for primary analysis
- c. If yes, proceed to step 3

**Step 3**

- a. Data further analysed with a Bland-Altman plot and summary statistics. Qualitative and quantitative assessment of systematic bias, limits of agreement, and note if there are any points felt to be outliers.
- b. Expert decision whether biomarker should be re-classified as having high reliability?
- c. If yes, biomarker taken forward to the inter-observer interpretation stage
- d. If no, biomarker not taken forward

**Inter-observer reliability data****Step 1**

- a. Is the overall inter-observer ICC greater than or equal to 0.9?
- b. If yes, the biomarker classified as having high reliability.
- c. If no, proceed to step 2.

**Step 2**

- a. Was poor agreement caused by a small number of outlier comparisons from one reader?
- b. Was poor agreement attributable due to a single reader with a systematic bias?
- c. Were limits of agreement consistent with acceptable precision?
- d. Based on a-c assessment biomarker classified as having adequate reliability or rejected from further evaluation.

**Results from statistical assessment**

The results from the intra- and inter-rater reliability studies is shown in etable-2.

**eTable-1: Leukocyte biomarkers evaluated**

<b>Leukocyte subset</b>	<b>Biomarker measurement description</b>
<b>Neutrophil biomarkers (N = 12 biomarkers)</b>	MFI for CD14, CD15, CD24, CD35, CD64, CD312, CD11b, CD274, CD279
	CD62L low CD16 low neutrophil subset as proportion of total neutrophils
	CD16 high neutrophil subset as proportion of total neutrophils
	CD62L high CD16 mid neutrophil subset as proportion of total neutrophils
<b>Monocyte biomarkers (N = 22 biomarkers)</b>	MFI for CD14, CD15, CD24, CD35, CD64, CD312, CD11b
	MFI for HLA-DR as measured on total monocytes, classical monocyte subset, non-classical monocyte subset, and intermediate monocyte subset
	MFI for CD274 as measured on total monocytes, classical monocyte subset, non-classical monocyte subset, and intermediate monocyte subset
	MFI for CD279 as measured on total monocytes, classical monocyte subset, non-classical monocyte subset, and intermediate monocyte subset
	Classical, intermediate and non-classical monocyte subsets, all 3 as proportion of total monocytes
<b>Dendritic cell biomarkers (N = 6 biomarkers)</b>	MFI for HLA-DR measured on total dendritic cells
	Total dendritic cells, and myeloid dendritic cells, both as proportion of non-granulocyte cells
	Myeloid, plasmacytoid, and non-specific dendritic cell subtypes, as proportion of total dendritic cells
<b>Lymphocyte biomarkers (N = 2 biomarkers)</b>	MFI for CD274 and CD279 measured on CD8 lymphocytes
<b>Natural killer cell biomarkers (N = 5 biomarkers)</b>	Natural Killer cells and NKT cells, both measured as proportion of total lymphocytes
	Naïve, mature and cytotoxic NK subsets, measured as proportion of total Natural Killer cells

**eTable-2: Table of Intraclass correlation coefficients (ICC) from the intra- and inter-rater reliability studies for each of the 47 biomarkers. Biomarkers rejected on intra-rater reliability testing are shown in red. Biomarkers rejected on inter-rater reliability testing are shown in blue**

Marker	Inter-observer ICC	Intra-observer ICC		
		Edinburgh	Newcastle	London
Neutrophil CD14	1	1	1	1
Neutrophil CD15	1	1	1	1
Neutrophil CD24	1	1	1	1
Neutrophil CD35	1	1	1	0.9999
Neutrophil CD64	1	1	1	1
Neutrophil CD312	1	1	1	0.9995
Monocyte CD14	0.9998	1	1	0.9993
Monocyte CD15	0.9998	1	0.9998	0.9997
Monocyte CD24	0.999	0.9986	0.9996	0.999
Monocyte CD35	0.9992	0.9997	0.9997	0.9994
Monocyte CD64	0.9997	0.9998	0.9996	0.9993
Monocyte CD312	0.9943	0.9998	0.9997	0.9985
HLA-Dr expression on all dendritic cells (DCs)	0.7785	0.9557	0.9675	0.935
Myeloid DC as % of parent cell	0.829	0.8373	0.9942	0.7764
Non-specific DC as % of parent cell	0.864	0.6017	0.9873	0.9364
Plasmacytoid DC as % of parent cell	0.7611	0.9704	0.9796	0.9434
Total DC as % of non-granulocyte cells	0.7484	0.967	0.9582	0.9266
Myeloid DC as % of non-granulocyte cells	0.8208	0.9305	0.9961	0.8775
HLA-Dr expression on all monocytes	0.9994	0.9996	0.9994	0.9997
HLA-Dr expression on classical monocytes	0.9989	0.9997	0.9995	0.9997
HLA-Dr expression on non-classical monocytes	0.9299	0.9762	0.9933	0.9962
HLA-Dr expression on intermediate monocytes	0.9962	0.9976	0.9976	0.989
Classical monocytes, as % of all monocytes	0.929	0.9985	0.9938	0.9928
Non-classical monocytes, as % of all monocytes	0.9744	0.9887	0.9716	0.9907
Intermediate monocytes, as % of all monocytes	0.959	0.9929	0.9673	0.9678
Neutrophil CD11b.mfi	0.9999	1	0.9999	0.9999
Monocyte CD11b.mfi	0.9968	0.9978	0.9991	0.9995
Neutrophil CD16hi	0.7295	0.9843	0.8097	0.915
Neutrophil CD62Lhi/CD16mid	0.798	0.9844	0.802	0.9383
Neutrophil CD62Low/CD16low	0.9493	0.9962	0.9929	0.9827
CD274 expression on CD8 lymphocytes	0.812	0.5054	0.9903	0.9771
CD274 expression on classical monocytes	0.9997	0.9998	0.9999	0.9453
CD274 expression on non-classical monocytes	0.9855	0.6597	0.997	0.9182
CD274 expression intermediate monocytes	0.9793	0.9919	0.9963	0.9594
CD274 expression on neutrophils	0.9998	0.998	1	0.9949
CD274 expression on all monocyte	0.9997	0.9998	0.9997	0.9997
CD279 expression on CD8 lymphocytes	0.914	0.9937	0.9682	0.9925
CD279 expression on classical monocytes	0.9943	0.975	0.9993	0.9874
CD279 expression on non-classical monocytes	0.1717	-0.1038	0.9924	0.974
CD279 expression on intermediate monocytes	0.9242	0.9189	0.9908	0.9689
CD279 expression on neutrophils	0.9978	0.9977	0.9989	0.9966
CD279 expression on all monocytes	0.9935	0.9703	0.9989	0.9863
NK measured as % of total lymphocytes	0.9985	0.9998	0.9989	0.9963
NKT measured as % of total lymphocytes	0.9883	0.9986	0.9958	0.9979
Cytotoxic NK cells, measured as % of NK cells	0.951	0.9888	0.9602	0.8446
Mature NK cells, measured as % of NK cells	0.8212	0.9765	0.9882	0.916
Naïve NK cells, measured as % of NK cells	0.7978	0.9681	0.986	0.9348

**eTable-3: Rationale for Biomarkers selected for discriminant analysis in cross cohort comparison**

Biomarker	Biological role	Cross cohort Kruskal Wallis test	Expert assessment	Selection
<b>Neutrophil biomarkers</b>				
CD14	LPS receptor with TLR4	P < 0.0001	Values cross cohorts mainly within 0-100 MFI range so limited variability. Cell numbers high. Differences mainly between cohort 1 and cohorts 2&3 which had similar values and range. Overall values lower in cohort 1.	NO
CD15	Carbohydrate adhesion module	P < 0.0001	Values for MFI range widely to maximum >8000. Cell numbers high. Clear cross cohort differences: highest cohort 3; lowest cohort 2; intermediate cohort 1.	YES
CD24	Cell adhesion glycoprotein; mediates cell apoptosis. Neutrophil expression	P < 0.001	Values for MFI cross cohort range widely to >50000. Cell numbers high. Clear cross cohort differences: highest cohort 1&2 with wide variability; lowest in cohort 1. Potential biological significance	YES
CD35	Complement receptor (type 1).	P < 0.0001	Values for MFI range widely to maximum >60000. Cell numbers high. Clear cross cohort differences: highest cohort 2; lowest cohort 3; intermediate cohort 1.	YES
CD64	Fc-gamma receptor 1	P < 0.0001	Values for MFI range widely to maximum >20000. Cell numbers high. Clear cross cohort differences: highest cohort 2; lowest cohort 3; intermediate cohort 1.	YES
CD312	G-protein coupled molecule	P < 0.0001	Values for MFI range to maximum >3000. Cell numbers high. Clear cross cohort differences: highest cohort 2; lowest cohort 1; intermediate cohort 2.	YES
CD11b	Complement receptor 3	P < 0.0001	Values for MFI range widely to maximum >60000. Cell numbers high. Clear cross cohort differences: highest cohort 1; lower and similar in cohorts 2&3.	YES
CD62L low CD16 low as % total neutrophils	Exploratory group	P < 0.0001	Values for percent mostly <2% with small number of outliers. Percent in small numbers ranged to >5%. Cell numbers very low. Cross cohort differences lack potential for discrimination.	NO
CD274	PD1 ligand	P < 0.0001	Values for MFI range to maximum >1000. Cell numbers high. Clear cross cohort differences: highest cohorts 1&2; lowest 3.	YES
CD279	PD1	P < 0.0001	Values for MFI range to maximum ≈1000. Cell numbers high. Clear cross cohort differences: wide range of values in cohorts 1&2 with lower values than cohort 3. Values consistently high in cohort 3.	YES
<b>Monocyte biomarkers</b>				
CD14	LPS receptor with TLR4	P = 0.277	No cross cohort differences. Biomarker was mainly selected as monocyte selection marker	NO



CD15	Carbohydrate adhesion module	P = 0.036	Minimal cross cohort differences	NO
CD24	Cell adhesion glycoprotein; mediates cell apoptosis. Neutrophil expression	P < 0.017	Minimal cross cohort differences. Lacks biological plausibility for monocytes.	NO
CD35	Complement receptor (type 1).	P < 0.0001	Values for MFI range widely to maximum >40000. Cell numbers moderate. Clear cross cohort differences: highest cohorts 1&2; lowest cohort 3.	YES
CD64	Fc-gamma receptor 1	P < 0.0001	Values for MFI range widely to maximum >100000 (in cohort 1). Cell numbers intermediate. Clear cross cohort differences: highest cohorts 1&2; lowest cohort 3.	YES
CD312	EMR2 cell surface marker on monocytes	P = 0.009	Values for MFI range to maximum >6000. Cell numbers intermediate. Some cross-cohort differences: highest cohort 2; lower in cohorts 1&3.	YES
CD11b	Complement receptor 3	P < 0.0001	Values for MFI range widely to maximum >80000. Cell numbers intermediate. Some cross cohort differences: highest cohorts 1&2; lower cohorts 3.	YES
CD274 total monocytes	PD1 ligand - check point inhibitors family	P < 0.0001	Values for MFI range to maximum >1000. Cell numbers intermediate. Some cross cohort differences: highest cohorts 1&2; lowest 3.	YES
CD279 total monocytes	PD1 – check point inhibitors family	P < 0.0001	Values for MFI range to maximum ≈500. Cell numbers intermediate. Clear cross cohort differences: wide range of values in cohorts 1&2 with lower values than cohort 3. Values consistently high in cohort 3.	YES
HLA-DR total monocytes	Antigen presentation	P < 0.0001	Values for MFI range to >30000. Cell numbers high. Clear cross cohort differences with highest levels in cohort 3, lowest in cohort 2, and intermediate with wide range in cohort 1.	YES
Percent classical monocytes		P<0.0003	Although differences apparent across the three groups, the cell numbers for non-classical and intermediate monocyte groups low. General patterns suggest lower percentages of classical monocytes in cohort 2 relative to cohorts 1&3; lower percent non-classical monocytes in cohort 1 compared to cohorts 2&3; lower percent of intermediate monocytes in cohort 3 compared to cohorts 1&2. Likely mathematical linkage and collinearity between these biomarkers, which would be problematic in discriminant and multivariable analysis.	NO
Percent non-classical monocytes		P < 0.0001		
Percent intermediate monocytes		P < 0.0001		
CD274 on classical monocytes	PD1 ligand - check point inhibitors family	P < 0.0001	Although differences across groups exist, cell numbers small and absolute differences in MFI values between groups small. Likely mathematical linkage and collinearity with CD274 on total monocytes, which would be problematic in discriminant and multivariable analysis	NO
CD274 on intermediate monocytes	PD1 ligand - check point inhibitors family	P < 0.0001		
CD279 on classical monocytes	PD1 – check point inhibitors family	P < 0.0001	Although differences across groups exist, cell numbers small and absolute differences in MFI values between groups small. Likely mathematical linkage and collinearity with CD274 on total monocytes, which would be problematic in discriminant and multivariable analysis	NO
CD279 on intermediate monocytes	PD1 – check point inhibitors family	P < 0.0001		
HLA-DR on classical monocytes		P < 0.0001	Patterns all mirror differences across cohorts for HLA-DR on total monocytes. Cell numbers for non-classical and intermediate monocytes very low. Likely mathematical linkage and collinearity with HLA-DR on total monocytes, which would be problematic in discriminant and multivariable analysis	NO
HLA-DR on non-classical monocytes		P < 0.0001		

HLA-DR on intermediate monocytes		P < 0.0001		
<b>Lymphocyte biomarkers</b>				
CD279 on CD8 T cells	PD1 – check point inhibitors family	P < 0.0001	Cell numbers intermediate. Some cross cohort differences: highest cohorts 1 and 2.	YES


**eTable-4:** Members of the independent expert review group who reviewed the provisional data from reliability, cross cohort comparisons, and discriminant analysis for the primary and secondary outcomes. This group recommended the post hoc extreme phenotype analysis to further explore differences between patients who subsequently recovered quickly versus progressed to severe sepsis.

Name	Position, Institution
Mervyn Singer	Professor of Intensive Care Medicine, University College, London, UK
Jean-Daniel Chiche	Professor of Critical Care Medicine, Hospital Cochin, Paris, France
Paul Dark	Professor of Critical Care Medicine, University of Manchester, Manchester, UK


**eTable-5: Comparison of recent leukocyte biomarker studies using multi-site flow cytometry with standardisation for illness trajectory prediction <sup>2-4</sup>**

Study characteristics	Current study (EXPRESS) N=259	Guerin E et al <sup>4</sup> N=177	Daix T et al <sup>2</sup> N=781	Conway-Morris A et al <sup>3</sup> N=138
Primary objective	Predict deterioration to develop sepsis sepsis-3 sepsis within 24 or 72 hours	Predict early evolution (deterioration or stability/improvement) of sepsis at 48 hours	Predict early evolution (deterioration or stability/improvement) of sepsis	Validate <sup>6</sup> cellular markers of immune dysfunction to stratify risk of secondary infection
Case definition at sampling	Patients with suspected infection attending ED	Patients with sepsis, severe sepsis or septic shock	Patients with sepsis, severe sepsis or septic shock	Critically ill patients predicted to remain in ICU for >=48 hours
Sites (N)	4	1	11	4
Number of leukocyte biomarkers evaluated	47 leukocyte biomarkers including leukocyte subsets (see eTable-1) assessed for reliability, discriminant value, followed by best subsets logistic regression	24 markers and 23 leukocyte subsets CD36; CD2; CD294; CD19; CD16; CD45; CD11b; CD16; CD8; CD64; CD11c; CD10; CD24; CD34; CD123; CD138; CD4; CD38; CD25; CD56; CD127; CD3; CD116; HLA-DR	CD64; CD10; CD3; CD24; CD11b; CD16; CD45	Neutrophil Cd88; Monocyte HLA-DR; proportion of regulatory T cell subsets
Key findings	Optimum biomarker combination of increased neutrophil CD24 and neutrophil CD279, and reduced monocyte HLA-DR expression to predict subsequent deterioration to sepsis	Immature granulocytes (CD10dim CD16dim) predicted clinical deterioration	Immature granulocytes associated with clinical worsening, when associated with T cell lymphopenia	Confirmed our previous findings <sup>6</sup>
Comparison of key findings of other studies with our EXPRESS study		CD16low subset did not have cross cohort discrimination in our EXPRESS study	CD64 MFI had univariate association, which disappeared with best-subsets logistic regression. Lymphopenia did not have cross cohort discrimination; CD24 expression in neutrophils was associated with clinical deterioration in our EXPRESS study	Different study population; HLA-DR was associated with clinical deterioration to sepsis in our EXPRESS study
Biological relevance of key markers reported in each study		Myeloid derived immature granulocytes appear cytotoxic towards T lymphocytes	CD64 is a Fc gamma receptor expressed on leukocytes; consistently reported as a diagnostic marker for sepsis	

**eFigure-1: Flow diagram showing the decision analysis for assessing intra- and inter-rater reliability for the 47 biomarkers, and selecting biomarkers considered reliable for evaluation in cross cohort comparisons. This algorithm is replicated as presented in the protocol manuscript <sup>1</sup>.**




**eFigure-2: Extreme phenotype derivation**




## eFigure-3: Cross cohort comparison of significant markers taken forward for further evaluation

### eFigure-3a: Neutrophil markers




# eFigure-3: Cross cohort comparison of significant markers taken forward for further evaluation

## eFigure-3b: monocyte biomarkers and CD279 on CD8-T cells





**eFigure-4: Biomarker profile differences in the well versus sick extreme phenotype**



## REFERENCES

1. Datta D, Conway Morris A, Antonelli J, et al. Early PREdiction of Severe Sepsis (ExPRES-Sepsis) study: protocol for an observational derivation study to discover potential leucocyte cell surface biomarkers. *BMJ Open*. 2016;6(8):e011335.
2. Daix T, Guerin E, Tavernier E, et al. Multicentric Standardized Flow Cytometry Routine Assessment of Patients With Sepsis to Predict Clinical Worsening. *Chest*. 2018.
3. Conway Morris A, Datta D, Shankar-Hari M, et al. Cell-surface signatures of immune dysfunction risk-stratify critically ill patients: INFECT study. *Intensive Care Med*. 2018;44(5):627-635.
4. Guerin E, Orabona M, Raquil MA, et al. Circulating immature granulocytes with T-cell killing functions predict sepsis deterioration\*. *Crit Care Med*. 2014;42(9):2007-2018.
5. Altman DG. *Practical statistics for medical research*. London: Chapman & Hall 2010.
6. Conway Morris A, Anderson N, Brittan M, et al. Combined dysfunctions of immune cells predict nosocomial infection in critically ill patients. *Br J Anaesth*. 2013;111(5):778-787.

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Manuscript reference; page number
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Title; Page-1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Abstract; Page-5 and Page-6
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Introduction; Page-7 and Page-8
Objectives	3	State specific objectives, including any prespecified hypotheses	Introduction Page-7 and Page-8; Parah-3
Methods			
Study design	4	Present key elements of study design early in the paper	Methods: Page-8, 9, 10, 11, 12, and Page-13 Electronic supplement; Page 2, 3, 4, 5, 6, 7 and Page-8
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Methods: Page-8, 9, 10, 11, 12, and Page-13 Electronic supplement
Participants	6	(a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	Methods: Page-8 Online only supplement; Page-2,3,
		(b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed	Not applicable
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Methods: Page-8, 9, 10, 11, 12, and Page-13 Online only supplement; Page-4,5, 6, 7 and Page-8 Statistics Page-6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	n/a
Bias	9	Describe any efforts to address potential sources of bias	Discussion; Page 18
Study size	10	Explain how the study size was arrived at	Methods Page 10
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Statistics; Page 10, 11, 12 and Page-13
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Statistics; Page 10, 11, 12 and Page-13
		(b) Describe any methods used to examine subgroups and interactions	Statistics; Page 10, 11, 12 and Page-13
		(c) Explain how missing data were addressed	Statistics; Page 10, 11, 12 and Page-13
		(d) Cohort study—If applicable, explain how loss to follow-up was addressed	Statistics; Page 10, 11, 12 and Page-13
		(e) Describe any sensitivity analyses	N/a

<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Page-13 and Page-14
		(b) Give reasons for non-participation at each stage	n/a
		(c) Consider use of a flow diagram	n/a
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Table-1
		(b) Indicate number of participants with missing data for each variable of interest	As above
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	Table-1
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	Table-1; Figure-1; eTable-2; Table-3
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Table-3
		(b) Report category boundaries when continuous variables were categorized	Table-3
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	AUROC and Odds ration with each SD increase in biomarker value
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	n/a
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	Page 16; Parah-2
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Page 18
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Discussion: Pages 16, 17, 18, and Page-19
Generalisability	21	Discuss the generalisability (external validity) of the study results	Discussion: Page Page-16 paragraph-; Page-19
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page-3

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies. **Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).